Table Info

Table 1.

PARPi and survival outcomes in mCRPC: main trial presented at ASCO GU 2023

Trial	Line setting	HRR status/BRCA status	Median FU (months)	rPFS (Months; experimental vs. standard)	OS (Months; experimental vs. standard)
PROpel (Olaparib/placebo + abiraterone)	1L mCRPC	HRRm (30%)/non-HRRm BRCAm (10%)/overall population	36.6 m	ITT: 24.8 vs. 16.6; HR: 0.66, 95% CI: 0.54–0.81, P < 0.001 HRRm: NR vs. 13.9; HR: 0.50, 95% CI: 0.34–0.73 non-HRRm: 24.1 vs. 19.0; HR: 0.76, 95% CI: 0.60–0.97 BRCAm: NR vs. 8.4; HR: 0.23, 95% CI: 0.12–0.43 non-BRCAm: 24.1 vs. 19.0; HR: 0.76, 95% CI: 0.61–0.94	ITT: 42.1 vs. 34.7 maturity 47.9%; HR: 0.81, 95% CI: 0.67–1.00; P = 0.0544 HRRm: NR vs. 28.5; HR: 0.66, 95% CI: 0.45–0.95 non-HRRm: 42.1 vs. 38.9; HR: 0.89, 95% CI: 0.70–1.14 BRCAm: NR vs. 23.0; HR: 0.29, 95% CI: 0.14–0.56 non-BRCAm: 39.6 vs. 38.0; HR: 0.91, 95% CI: 0.73–1.13
TALAPRO-2 (Talazoparib/placebo + enzalutamide)	1L mCRPC	HRRm (20%)/non-HRRm BRCA1m (5%) BRCA2m (23%)	24 m	ITT: not reached vs. 21.9; HR: 0.63, 95% CI: 0.51–0.78; P < 0.001 HHRm: 27.9 vs. 16.4; HR: 0.46, 95% CI: 0.30–0.70, P < 0.001 non-HRRm: not reached vs. 22.5; HR: 0.70, 95% CI: 0.54–0.89; *P = 0.009	ITT: HR: 0.89; P = 0.35 (no mature data—only 31% of events)
MAGNITUDE (IA2) Niraparib/Placebo + Abiraterone and prednisone	1L mCRPC	HRRm (100%) BRCAm (53.2%)	35 m	HHRm: 16.7 vs. 13.7; HR: 0.76, 95% CI: 0.60–0.97 BRCAm: 19.5 vs. 10.9; HR: 0.55, 95% CI: 0.39–0.78, P = 0.0007	HHRm: 29.3 vs. 32.2; HR: 1.01, 95% CI: 0.75–1.36 BRCAm: 30.4 vs. 28.6; HR: 0.788; 95% CI: 0.554–1.120; P = 0.1828

PARPi: poly (ADP-ribose) polymerase inhibitor; mCRPC: metastatic castration resistant prostate cancer; HRR: homologous recombination repair; HRRm: HRR mutated; BRCA: breast cancer; rPFS: radiological progression-free survival; OS: overall survival; ITT: intention to treatment; BRCAm: BRCA mutated; FU: follow-up; * same BRCAm rates in the two treatment groups; NR: not reported

Declarations

Author contributions

MP: Conceptualization, Investigation, Writing—original draft. VC: Conceptualization, writing—review & editing. MRD: Validation, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. 2023;129:904–16. [DOI] [PubMed] [PMC]

McNevin CS, Cadoo K, Baird A, Finn SP, McDermott R. PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures. Cancers (Basel). 2022;14:4751. [DOI] [PubMed] [PMC]

Taylor AK, Kosoff D, Emamekhoo H, Lang JM, Kyriakopoulos CE. PARP inhibitors in metastatic prostate cancer. Front Oncol. 2023;13:1159557. [DOI] [PubMed] [PMC]

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373:1697–708. [DOI] [PubMed] [PMC]

Messina C, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E, et al. BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. J Oncol. 2020;2020:4986365. [DOI] [PubMed] [PMC]

Pritchard CC, Mateo J, Walsh MF, Sarkar ND, Abida W, Beltran H, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016;375:443–53. [DOI] [PubMed] [PMC]

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018;174:758–69. Erratum in: Cell. 2018;175:889. [DOI] [PubMed] [PMC]

Fettke H, Dai C, Kwan EM, Zheng T, Du P, Ng N, et al. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype. EBioMedicine. 2023;95:104738. [DOI] [PubMed] [PMC]

Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411:366–74. [DOI] [PubMed]

10.

McVey M, Lee SE. MMEJ repair of double-strand breaks (director’s cut): deleted sequences and alternative endings. Trends Genet. 2008;24:529–38. [DOI] [PubMed] [PMC]

11.

Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MIR, et al. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature. 2015;518:258–62. [DOI] [PubMed] [PMC]

12.

Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun. 1963;11:39–43. [DOI] [PubMed]

13.

Brandsma I, Gent DC. Pathway choice in DNA double strand break repair: observations of a balancing act. Genome Integr. 2012;3:9. [DOI] [PubMed] [PMC]

14.

Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem. 2010;79:181–211. [DOI] [PubMed] [PMC]

15.

Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011;12:68–78. [DOI] [PubMed] [PMC]

16.

Tutt A, Bertwistle D, Valentine J, Gabriel A, Swift S, Ross G, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 2001;20:4704–16. [DOI] [PubMed] [PMC]

17.

Lord CJ, Garrett MD, Ashworth A. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin Cancer Res. 2006;12:4463–8. [DOI] [PubMed]

18.

McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66:8109–15. [DOI] [PubMed]

19.

Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4:814–9. [DOI] [PubMed]

20.

Robinson D, Allen EMV, Wu Y, Schultz N, Lonigro RJ, Mosquera J, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–28. [DOI] [PubMed] [PMC]

21.

Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, et al. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nat Commun. 2023;14:252. [DOI] [PubMed] [PMC]

22.

Wu Y, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, et al. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell. 2018;173:1770–82. [DOI] [PubMed] [PMC]

23.

Antonarakis ES, Velho PI, Fu W, Wang H, Agarwal N, Santos VS, et al. CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precis Oncol. 2020;4:370–81. [DOI] [PubMed] [PMC]

24.

Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094–108. [DOI] [PubMed]

25.

Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, et al.; MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023;41:3339–51. [DOI] [PubMed] [PMC]

26.

Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402:291–303. [DOI] [PubMed]

27.

Rao A, Moka N, Hamstra DA, Ryan CJ. Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now? Cancers (Basel). 2022;14:801. [DOI] [PubMed] [PMC]

28.

Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8:374. [DOI] [PubMed] [PMC]

29.

Buis J, Wu Y, Deng Y, Leddon J, Westfield G, Eckersdorff M, et al. Mre11 nuclease activity has essential roles in DNA repair and genomic stability distinct from ATM activation. Cell. 2008;135:85–96. [DOI] [PubMed] [PMC]

30.

Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, et al. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res. 2010;70:5389–98. [DOI] [PubMed]

31.

Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012;2:1134–49. [DOI] [PubMed] [PMC]

32.

Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, et al. Androgen receptor inhibitor-induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10:eaam7479. [DOI] [PubMed] [PMC]

33.

Bourlon MT, Valdez P, Castro E. Development of PARP inhibitors in advanced prostate cancer. Ther Adv Med Oncol. 2024;16:17588359231221337. [DOI] [PubMed] [PMC]

34.

Illuzzi G, Staniszewska AD, Gill SJ, Pike A, McWilliams L, Critchlow SE, et al. Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022;28:4724–36. [DOI] [PubMed] [PMC]

35.

Azad A, Voskoboynik M, Palma dos Reis AF, Joshua AM, Weickhardt AJ, Jones RJ, et al. Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC). J Clin Oncol. 2023;41:TPS296. [DOI]

36.

Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al.; TRITON3 Investigators. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023;388:719–32. [DOI] [PubMed] [PMC]

37.

Abida W, Campbell D, Patnaik A, Bryce AH, Shapiro J, Bambury RM, et al. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol. 2023;84:321–30. [DOI] [PubMed]

38.

Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:162–74. [DOI] [PubMed] [PMC]

39.

Bono Jd, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382:2091–102. [DOI] [PubMed]

40.

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al.; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;383:2345–57. [DOI] [PubMed]

41.

Saad F, Armstrong AJ, Thiery-Vullemin A, Oya M, Loredo E, Procopio G, et al. PROpel: phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40:11. [DOI]

42.

ESMO [Internet]. Lugano: European Society for Medical Oncology (ESMO); c2024 [cited 2024 July 19]. Available from: https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards/scorecard-365-1

43.

Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023;34:772–82. [DOI] [PubMed]

44.

Chi KN, Castro E, Attard G, Smith MR, Sandhu SK, Efstathiou E, et al. LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: three years update and final analysis (FA) of MAGNITUDE. Ann Oncol. 2023;34:S1326. [DOI]

45.

Rao A, Heller G, Ryan CJ, VanderWeele DJ, Lewis LD, Tan A, et al. Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40:TPS194. [DOI]

46.

Rathkopf DE, Chi KN, Olmos D, Cheng HH, Agarwal N, Graff JN, et al. AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). J Clin Oncol. 2021;20;39:TPS176. [DOI]

47.

Gross-Goupil M, Thurin NH, Rouyer M, Jové J, Haaser T, Rebillard X, et al. Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment. J Clin Oncol. 2020;38:5570. [DOI]

48.

Messina C, Giunta EF, Signori A, Rebuzzi SE, Banna GL, Maniam A, et al. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis. Eur Urol Oncol. 2024;7:179–88. [DOI] [PubMed]